

# Freedom of Information Request: Our Reference CTMUHB\_376\_22

## You asked:

I would be grateful if you could complete the answers to the questions given below which aims to give me top level information on the number of patients treated for different types of breast cancer.

I am interested to know the total number of patients with **breast cancer** treated with medicines between **Apr 2022 and Aug 2022**. When responding to the questions below please count all patients treated with chemotherapies, biological agents, hormonal therapies etc., but exclude patients treated with surgery only and/or radiotherapy only.

1. How many patients with breast cancer were treated in total?

2. How many patients with breast cancer were treated at the following stages?

- Early breast cancer (stages I or II)
- Locally advanced breast cancer (stage III)
- Metastatic breast cancer (stage IV)

3. How many patients with breast cancer were treated in the following categories of tumour characteristics and staging?

• Early breast cancer	Neoadjuvant	HR+ve ( <i>ER+ve &amp;/or PR+ve</i> )	<input type="text"/>
• Early breast cancer	Adjuvant	HR+ve ( <i>ER+ve &amp;/or PR+ve</i> )	<input type="text"/>
• Early breast cancer	Neoadjuvant	HR+ve, HER2+ve	<input type="text"/>
• Early breast cancer	Adjuvant	HR+ve, HER2+ve	<input type="text"/>
• Early breast cancer	Neoadjuvant	HR+ve, HER2-ve	<input type="text"/>
• Early breast cancer	Adjuvant	HR+ve, HER2-ve	<input type="text"/>
• Early breast cancer	Neoadjuvant	HR+ve, HER2-ve, node positive	<input type="text"/>
• Early breast cancer	Adjuvant	HR+ve, HER2-ve, node positive	<input type="text"/>
• Early breast cancer	Neoadjuvant	HER2+ve, node positive	<input type="text"/>
• Early breast cancer	Adjuvant	HER2+ve, node positive	<input type="text"/>
• Early breast cancer	Neoadjuvant	BRCA1/2 germline mutation positive	<input type="text"/>
• Early breast cancer	Adjuvant	BRCA1/2 germline mutation positive	<input type="text"/>
• Early breast cancer	Neoadjuvant	Triple negative	<input type="text"/>
• Early breast cancer	Adjuvant	Triple negative	<input type="text"/>
• Early breast cancer	All	PIK3CA mutation	<input type="text"/>
• Locally advanced	All	HR+ve ( <i>ER+ve &amp;/or PR+ve</i> )	<input type="text"/>
• Locally advanced	All	HER2+ve	<input type="text"/>
• Locally advanced	All	HR+ve, HER2-ve	<input type="text"/>
• Locally advanced	All	BRCA1/2 germline mutation positive	<input type="text"/>
• Locally advanced	All	Triple negative, PD-L1 positive	<input type="text"/>
• Locally advanced	All	Triple negative, PD-L1 negative	<input type="text"/>
• Locally advanced	All	PIK3CA mutation	<input type="text"/>
• Metastatic	All	HR+ve ( <i>ER+ve &amp;/or PR+ve</i> )	<input type="text"/>
• Metastatic	All	HER2+ve	<input type="text"/>
• Metastatic	All	HR+ve, HER2-ve	<input type="text"/>

• Metastatic	All	BRCA1/2 germline mutation positive	
• Metastatic	All	Triple negative, PD-L1 positive	
• Metastatic	All	Triple negative, PD-L1 negative	
• Metastatic	All	PIK3CA mutation	

**Definitions**

*HER2 = human epidermal growth factor 2 protein;*

*HR+ve = hormone receptor positive (oestrogen receptor positive, ER+ve, progesterone receptor positive, PR+ve, or both ER+ve and PR+ve);*

*Triple negative = HER2-ve and HR-ve (ER-ve and PR-ve)*

*BRCA = breast cancer gene;*

*PD-L1 = programmed death-1 ligand;*

*PIK3CA = Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha*

**Our response:**

We can confirm that Cwm Taf Morgannwg University Health Board does not hold the information you require. Cwm Taf residents receive breast cancer treatment from the Velindre Cancer Centre, Velindre NHS Trust. Therefore, you will need to redirect your request to Velindre, who provide these services to Cwm Taf residents.

Contact details for Velindre are shown in the following link:

<http://www.velindre-tr.wales.nhs.uk/freedom-of-information-contacts>